261 related articles for article (PubMed ID: 17876386)
1. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin and torsade de pointes.
Dale KM; Lertsburapa K; Kluger J; White CM
Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
[TBL] [Abstract][Full Text] [Related]
4. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
5. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin-induced torsades de pointes.
Sherazi S; DiSalle M; Daubert JP; Shah AH
Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
[TBL] [Abstract][Full Text] [Related]
7. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
[TBL] [Abstract][Full Text] [Related]
8. Update on the cardiac safety of moxifloxacin.
Haverkamp W; Kruesmann F; Fritsch A; van Veenhuyzen D; Arvis P
Curr Drug Saf; 2012 Apr; 7(2):149-63. PubMed ID: 22873499
[TBL] [Abstract][Full Text] [Related]
9. Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies.
Baas T; Gräfe K; Khawaja A; Dössel O
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3796-9. PubMed ID: 22255166
[TBL] [Abstract][Full Text] [Related]
10. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Chiba K; Sugiyama A; Hagiwara T; Takahashi S; Takasuna K; Hashimoto K
Eur J Pharmacol; 2004 Feb; 486(2):189-200. PubMed ID: 14975708
[TBL] [Abstract][Full Text] [Related]
11. [Practical ECG problems in the elderly patient. Case number 16. Moxifloxacin-associated QT interval prolongation].
Farhoumand AD; Trombert V; Eusebio J
Rev Med Suisse; 2011 Mar; 7(286):624-5. PubMed ID: 21510347
[No Abstract] [Full Text] [Related]
12. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
13. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
14. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Frothingham R
Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
[TBL] [Abstract][Full Text] [Related]
15. Drug Points: tachycardia associated with moxifloxacin.
Siepmann M; Kirch W
BMJ; 2001 Jan; 322(7277):23. PubMed ID: 11141146
[No Abstract] [Full Text] [Related]
16. A practical approach to torsade de pointes.
Roden DM
Clin Cardiol; 1997 Mar; 20(3):285-90. PubMed ID: 9068917
[TBL] [Abstract][Full Text] [Related]
17. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
[TBL] [Abstract][Full Text] [Related]
18. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin-induced hypoglycemia in a non-diabetic patient.
Mandavia DR; Virpariya MM; Patel TK; Tripathi CB
Curr Drug Saf; 2012 Apr; 7(2):183-5. PubMed ID: 22873504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
